Remarkable improvement of primary orthostatic tremor using perampanel.

Abstract

Management of primary orthostatic tremor (POT) remains challenging, and medication is often ineffective. We report the case of a 53-year-old female with orthostatic tremor for 6 years who was refractory to gabapentin, clonazepam, primidone and propranolol. After treatment with 4 mg/day perampanel, she reported almost complete resolution of tremor. The diagnosis of POT was confirmed by tremor analysis using surface electromyography. Our report shows the potential use of the novel AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist perampanel for the treatment of POT. To date, only two similar patients, one refractory to treatment and the other previously treated with clonazepam only, have been reported. We would like to note that our patient was refractory to all previous therapy and responded to a low dose of perampanel without side effects. The striking clinical improvement suggests a putative role of glutamate in the pathophysiology of orthostatic tremor.

• Authors: Marcus Grobe-Einsler, Oliver Kaut
• Journal: Neurological research and practice (Neurol Res Pract) Vol. 2 Pg. 3 ( 2020) ISSN: 2524-3489 [Electronic] England
• PMID: 33324909 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2020.